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Abstract 
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in 
modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review 
(ICER). The principal objection to ICER reports has been that their modeled claims fail the standards of normal science: they are best 
seen as pseudoscience. The purpose of this latest commentary is to consider the recently released ICER evidence report for Janus Kinase 
(JAK) Inhibitors. As ICER continues, in the case of JAK Inhibitors, to apply its modeled cost utility framework with consequent 
recommendations for pricing adjustments, these recommendations also lack credibility. In contrast with previous ICER evidence reports, 
the present report adopts only a 12-month timeframe, one due, in large part, to ICER being unable to justify assumptions to drive its 
construction of imaginary worlds beyond 12 months. This commentary emphasizes again, why the ICER methodology fails to meet the 
standards of normal science. Claims made by ICER for the competing JAK Inhibitor therapies lack credibility, are impossible to evaluate, 
let alone replicate across treatment settings. Even so, it is important to examine a number of key elements in the ICER invention of the 
12-month JAK Inhibitor imaginary world. While this does not imply any degree of acceptance of the ICER methodology, one element 
that merits particular attention is the failure of the ICER modeling to meet logically defensible measurement standards in its application 
of generic health related quality of life (HRQoL) ordinal metrics to create its QALY claims. The failure to meet the required standards of 
fundamental measurement means that the cost-per-QALY claims are invalid. This raises the issue of the application of Rasch 
Measurement Theory (RMT) in instrument development and the potential role of patient centric outcome (PCO) instruments that 
represent the patient voice in value claims. The case made here is that the ICER approach should be abandoned as an unnecessary 
distraction. If we are to meet standards for the discovery of new facts in therapy response then our focus must be on proposing credible, 
evaluable and replicable claims within disease states. Instruments, such as the Rheumatoid Arthritis Quality of Life (RAQoL) 
questionnaire that build on the common construct that QoL is the extent to which human needs are fulfilled should be the basis for 
value claims.  HRQoL Instruments that are clinically focused and reflect the value calculus of providers and not patients in measuring 
response by symptoms and activity limitations are irrelevant.   This puts to one side the belief that incremental cost-per-QALY models, 
the construction of imaginary worlds are, in any sense, a ‘gold standard’; a meme embraced by the health technology assessment 
profession. Claims for incremental cost per QALY outcomes and recommendations for pricing and access driven by willingness to pay 
thresholds are irrelevant to formulary decisions.  
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____________________________________________________________________________________________________________ 
Introduction 
The construction of assumption driven imaginary worlds to 
support incremental cost-per-quality adjusted life year (QALY) 
claims for pricing and access recommendations is the hallmark 
of the Institute for Clinical and Economic Review’s (ICER) 
business model. ICER’s latest evidence report on Janus Kinase 
(JAK) inhibitors in rheumatoid arthritis (RA) follows this model. 
The JAK inhibitors under review are upadacitinib (RINVOQ, 
AbbVie), tofacitinib (Xeljanz, Pfizer) and baricitinib (Olumiant, 
Lilly). In each case the modeled JAK inhibitor and adalimumab 
were compared as add on therapies to conventional DMARD 
therapy in the targeted immune modulator (TIM) treatment  
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arms. First released on 26 September 2019, the ICER evidence 
report for JAJK inhibitors was subsequently withdrawn with a 
revised report released on 11 October 2019, followed by a 
further evidence report for review by the ICER convened 
California Technology Assessment Forum on 26 November 
2019 1 2 3. The final evidence report was released on 9 January, 
2020 4.  At the same time, this commentary also considers a 
complementary model framework, the IVI-RA which is an on-
line open source imaginary model that has been proposed to 
evaluate therapy sequences in similar RA populations to those 
considered by ICER  5 6 7. 
 
The present commentary is concerned with the final evidence 
report and the modeled economic evaluation. The purpose of 
this commentary is to point out that the ICER model and 
consequent recommendations for pricing and access to JAK 
inhibitors fail to meet the standards of normal science. .A 
similar conclusion applies to the IVI-RA model. They are 
irrelevant to formulary decisions. 
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Previous commentaries have pointed out, including a previous 
commentary on targeted immune modifiers (TIMs) in RA that if 
an imaginary incremental cost per QALY model is constructed, 
then any number of similar models, with the same fatal flaws, 
can be constructed 8 9 10 11 12. These commentaries made the 
case that applying the ICER methodology is an intellectual and 
analytical dead-end; none of the claims made for comparative 
cost-effectiveness are credible, evaluable and replicable. As 
such, formulary committees would have no idea whether ICER 
recommendations were right or wrong; they would never know 
and were never expected to know.  
 
The arguments against the ICER evidence report for JAK 
inhibitors is an exemplar of the irrelevance of a reference case 
methodology to support recommendations for pricing and 
access for any pharmaceutical product or devices. Certainly, the 
reference case methodology is seen as the ‘state of the art’ in 
health technology assessment which supports the construction 
of imaginary, simulated models projecting over the lifetime of 
a hypothetical patient cohort to generate incremental cost-per-
QALY claims. These claims are set against willingness to pay 
thresholds to convince an audience, who are typically non-
technical, to take at face value recommendations for product 
pricing and access based on a hypothetical world.  It is 
acknowledged by technology assessment groups that these are 
artificial (yet ‘realistic’) but that their redeeming feature, 
apparently, is that they generate ‘approximate information’ for 
decision makers; or, more precisely, ‘imaginary’ information (or 
disinformation)13.  
 
The IVI-RA model suffers from the same lack of scientific merit 
at the ICER JAK inhibitor model. It is, once again, best seen as   
pseudoscience; it fails the demarcation test. It opens up the 
prospect for a multiverse of more complex imaginary worlds to 
support the apparent need by decision makers for more 
hypothetical and ‘approximate information’ on an unknown 
future.  
 
There are more fundamental flaws. ICER claims for product 
value do not reflect the interests of patients in RA. The 
reference case assumes that a generic measure of health 
related quality of life (HRQoL) is appropriate to evaluating the 
benefits of competing therapies. This belief has been 
challenged repeatedly over the past 40 years by first, the needs 
based framework for evaluating quality of life (QoL) and, more 
recently, since the late 1990s, supplementing the needs 
approach with the application of Rash Measurement Theory 
(RMT) to ensure unidimensionality with interval scoring 14 15.   
 
As detailed below, a generic multi-attribute instrument such as 
the EQ-5D-3L, the backbone of the ICER cost-per-QALY 
imaginary worlds, fails standards for fundamental 
measurement.   Rather than providing a unidimensional metric 
that supports RMT, it generates an ordinal manifest score that 
precludes basic arithmetic operations. This is seen, for example, 
if wanted to assess effect size. It would be a logically invalid 
measure 16 17.  Despite the demonstrated disease-area specific 
superiority of needs base QoL instruments, ICER persists in 
modeling the EQ-5D-3L which, at best is a limited health related 
quality of life (HRQoL) instrument without a clearly defined 
construct. As argued here, HRQoL instruments, despite their 
inability to provide more than manifest ordinal scores, are not 
relevant if our objective is to assess the QoL impact of therapy 
interventions. They are clinically focused, representing the 
interest of physicians and not patients. They take no account of 
the needs fulfillment of patients with RA and the extent to 
which competing therapies impact the lives and needs of the 
patient 18. This points to the relevance, not of a generic 
instrument but ones that are disease specific and patient 
centric 19 20.  If we want to assess patient needs, then we don’t 
need QALYs. 
 
Unfortunately, as we also argue below in the case of RA, ICER 
has nowhere to go. If the case is made, which it has been in the 
literature for some 20 years and more, that ordinal measures 
have to be abandoned, then the ICER cost-per-QALY reference 
case collapses. It follows that the ICER business model also 
collapses; apart from the nonsense of attempting to 
construction imaginary lifetime reference case worlds. It is, 
perhaps, surprising that ICER launched itself as NICE-lite 
(National Institute for Health and Clinical Excellence) when the 
focus in QoL is away  from HRQoL and towards needs based, 
RMT consistent, disease specific outcomes instruments. 
Indeed, as we also note, the debates over alternative value 
assessment frameworks come down to a failure to take explicit 
account of needs-based assessments instead of trying to ‘bolt-
on’ other criteria to a core HRQoL model. 
 
The ICER reference case model, to include the IVI-RA, is an 
unnecessary distraction in health system decision making. If 
formulary committees and insurers are considering factoring in 
the ICER recommendations as ‘approximate information’ to 
support pricing and access, they should put such claims to one 
side. Any formulary decision must be evidence based where the 
evaluation techniques meet the standards of normal science. 
Decisions should not be based on imaginary worlds, as 
attractive and ‘probably realistic’ they may be to the believer. 
Admitting that the focus is not on testing hypotheses for 
product impact and cost-effectiveness but on providing 
imaginary ‘approximate information’ is not an admissible 
defense.  
 
The Intelligent Design Meme 
Unfortunately, ICER is not alone in its promotion of intelligent 
design in health technology assessment. This is the position of 
the leading health technology assessment group in the US, the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR)  Creating imaginary worlds to support 
imaginary claims is, of course, an easy way out. It puts to one 
side the discovery of new facts in favor of fabrication. The need 
to fabricate is defended on the grounds that we lack the 
required information for hypothesis testing which then forces 
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us to the reference case imaginary worlds; this is an absurd 
position.  Rather than taking refuge in imaginary worlds our 
focus must be on the discovery of new facts to support 
formulary decisions that meet both the needs of patients as 
well as those of the health system.  
 
Unfortunately, the intelligent design health technology 
assessment meme, as a unit of cultural transmission, is well 
established. It will take a concerted effort, not only in therapy 
assessments for target RA populations, to abandon this 
reference case dogma, but to put resources into ensuring in 
both randomized clinical trial (RCT) protocols and claim 
assessment that needs based instruments are front and center. 
 
A final point: irrespective of the disease area or the therapies 
chosen for review by the ICER team, the model selected for the 
respective evidence report is merely one in a potential 
multiverse of imaginary constructed models. This is 
underscored in the case of RA by the need to construct utility 
manifest scores, by crosswalking from clinical markers. As few 
clinical trials capture specific quality of life metrics utilizing 
generic preference-based multi-attribute instruments, ICER is 
faced with the need to construct utility values to generate QALY 
estimates. This adds a further element of unreality to the ICER 
model as there are a substantial number of generic utility value 
options open that can be emulated as well as a smorgasbord of 
competing techniques and algorithms available for 
crosswalking to create utility values and the range of potential 
crosswalking techniques. In short, while ICER  may claim pole 
position in imaginary evidence constructions in the US, the 
evidence report model of ICER can be easily challenged by other 
imaginary constructs given the options open to change 
assumptions and the construction of competing models within 
the same reference case  paradigm 21 22 23. Fortunately, we do 
not have to go to the lengths of comparing imaginary claims. 
We can simply put all imaginary constructs to one side. 
 
Initial Scoping and Response 
The original ICER scoping document was characterized by ICER 
as a condition update to the 2017 ICER report on targeted 
immune modifiers (TIMs). Public responses from stakeholders 
was requested by 1 May 2019 and a revised scoping document 
issued on 9 May, 2019 24. The earlier report presented an 
imaginary modeled assessment of the comparative clinical 
effectiveness and value of multiple TIMs for moderately to 
severe active rheumatoid arthritis both as monotherapy and in 
combination with conventional DMARDS 25. The 2017 evidence 
reported was reviewed by the present author in an early 
commentary 4.  The commentary concluded:  Rather than 
attempting to inform decision makes through the construction 
of imaginary worlds, price negotiations should be predicated on 
evidence that meets the standards of normal science.  Unless 
evaluable and replicable claims are presented by ICER to 
support recommendations for price discounting, the 
recommendations should be rejected. This applies not only to 
the current recommendations for price discounting of TIMs, but 
to other ICER evidence reviews that have generated non-
evaluable claims. 
 
Initial stakeholder response to the ICER scoping document 
raised a number of concerns regarding issues to be addressed 
and the measurement of QoL; whether the focus should be on 
the clinical concept of health related quality of life (HRQoL) or 
the wider concept of quality of life (QoL)26. The Arthritis 
Foundation, to give one example, noted in its submission that 
in response to the final evidence report for the 2017 
assessment they were concerned that: ‘the study analysis was 
narrow and did not include a representative sample of people 
with RA, and therefore was not relevant to all people with RA; 
the conclusions reached were based on inadequate 
performance measures; the reliance on QALYs was 
inappropriate for this disease population; and there was an 
absence of real-world evidence for this disease population; and 
patient experience in the final analysis’ 27. As an exemplar, the 
Arthritis Foundation response points to a number of key issues: 
(i) the real world use of ICER reviews where ‘…many concerns 
remain about the core methodologies and their applicability to 
chronic disease states, particularly RA’; (ii) the application of 
point estimate averages of the value of treatments (that) 
become potentially very harmful, especially if these results are 
taken at face value and applied as umbrella statements on 
relative value across the entire population; (iii) avoiding 
heterogeneity  where the misuse of a single cost-effectiveness 
ratio ‘as a proxy for value for all potential patients  … is reduced 
access to a therapy for individuals for which that therapy would 
provide significant value if delivered in a timely fashion’ and (iv) 
the importance of a longitudinal focus in assessing the impact 
of RA. 
 
Narrowing the Focus: JAK Inhibitors 
In June 2019, ICER refocused its RA review and issued an 
updated scoping document 28. ICER decided to narrow the focus 
of its RA review on JAK inhibitors for two reasons: (i) the 
approval of baricitinib since the 2017 report for moderate-to-
severe RA and (ii) the expected approval in August 2019 of 
upadacitinib following the FDA acceptance for priority review. 
 
This revised review was to assess the comparative clinical 
effectiveness and value of JAK inhibitors for moderately to 
severely active RA, both as monotherapy and in combination 
with conventional DMARDS. The proposal was to update 
previous assessments with new trial data for JAK inhibitors 
together with a review of the clinical and economic evidence 
for infliximab-dvvb (Inflectra, Pfizer).  
 
The JAK Evidence Reports 
In the first evidence report presented by ICER (26 September, 
2019) for the JKAK inhibitors, the model took a base-case 
lifetime perspective. Patients from a hypothetical initial cohort 
remained in the model until death. All patients could transition 
to death from all causes and from RA-related mortality  The 
selected model generated constructed claims  for outcomes to 
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include imaginary lifetime costs, life years (LYs), quality 
adjusted life years (QALYs) and equal value of life years gained 
(evLYG). The incremental cost per evLYG was proposed to 
complement the cost per QALY calculations and provide 
policymakers with a broader view of cost effectiveness.  The 
model was constructed in hēRo3℠, with some components of 
the model, such as survival distributions, developed in RStudio 
(Version 1.1.463). The hēRo3 model is a Web-based, health 
economic modeling platform that supports the development of 
imaginary technology assessment worlds with both Markov 
cohort and partitioned survival models (Policy Analysis Inc., 
Brookline, MA).  
 
The September evidence report was rescinded within a few 
days and a revised evidence report released on 11 October 
2019).  ICER maintained, that following a review that suggested 
‘some of the assumptions and calculations’ might be re-
evaluated in the modeling apparently ‘to align … with how 
patients transition between these therapies in the real world’. 
The key changes in assumption were (i) to model how those 
who did not respond adequately to first line therapy would 
transition to a basket of targeted products and not palliative 
care and (ii) that cost-per-QALY claims were evaluated over one 
year and not a lifetime. This shorter time frame was selected as 
base-case because of uncertainties over the clinical 
differentiation of the target JAK therapies over time (i.e., 
insufficient data to support assumptions). The point to note is 
that the evidence base had not changed. ICER continued to 
point out in the overview of its assessment of long-term cost 
effectiveness that while the modification of their initial 
objective to assess the relative value of JAK inhibitors versus 
adalimumab for treatment after failure by a conventional 
DMARD was still the focus, they were unable, even with 
assumptions designed to create an imaginary world, to model a 
direct comparison of tofacitinib to adalimumab due to 
inadequate data in the TIM-naïve or TIM-experienced 
population. The same limitation applied in a comparison of 
upadacitinib to adalimumab in the TIM-experienced 
population. In the case of baricitinib in patients who failed TNF-
inhibitors, modeling attempts to compare it to adalimumab in 
the TIM-experienced population was considered impossible 
due to a lack of comparable data. 
 
However, as ICER notes as a rider to their evidence reports that 
when ‘new’ data emerge they may revisit the imaginary model 
and produce a new imaginary model report with value 
judgments. It is not clear how manufacturers, insurers and 
formulary committees would respond if they see the ICER 
model as one of many future imaginary iterations, none of 
which meet accepted standards for normal science. The result 
would be (i) a possible multiverse of base-line models and (ii) a 
budding of future models with a multiverse of imaginary 
‘modified’ models created from each initial base-line model, 
each claimed to provide necessary ‘approximate information’; 
a daunting prospect for decision makers trying to separate out 
one from many worlds.   
Meeting the Standards of Normal Science 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for products and devices 
is unexceptional. Since the 17th century, it has been accepted 
that if a research agenda is to advance, if there is to be an 
accretion of knowledge, there has to be a process of discovering 
new facts. Indeed, as early as the 16th century Leonardo da Vinci 
(1452 – 1519) in notes that appeared posthumously in 1540 for 
his Treatise on Painting (published in 1641) clearly anticipated 
the standards for the scientific method which were widely 
embraced a century later in rejecting thought experiments that 
fail the test of experience. By the 1660s, the scientific method, 
following the seminal contributions of Bacon, Galileo, Huygens 
and Boyle, had been clearly articulated by associations such as 
the Academia del Cimento in Florence (1657) and the Royal 
Society in England (founded 1660; Royal Charter 1662) with their 
respective mottos Provando e Riprovando (prove and again 
prove) and nullius in verba (take no man’s word for it) 29.  
By the early 20th century, standards for empirical assessment 
were put on a sound methodological basis by Popper (Sir Karl 
Popper 1902-1994) in his advocacy of a process of ‘conjecture 
and refutation 30 31 .  Hypotheses or claims must be capable of 
falsification; indeed, they should be framed in such a way that 
makes falsification likely. Life becomes more interesting if claims 
are falsified because this forces us to reconsider our models and 
the assumptions built into those models. This leads to the 
obvious point that claims or models should not be judged on the 
realism or reasonableness of assumptions or on whether the 
model ‘represents’ for a public advocacy research group such as 
ICER their perception of a future, yet unknown, reality.  
Although Popper’s view on what demarcates science (e.g., 
natural selection) from pseudoscience (e.g., intelligent design) is 
now seen as an oversimplification involving more than just the 
criteria of falsification, the demarcation problem remains 32.  
Certainly, there are different ways of doing science but what all 
scientific inquiry has in common is the ‘construction of 
empirically verifiable theories and hypotheses’. Empirical 
testability is the ‘one major characteristic distinguishing science 
from pseudoscience’; theories must be tested against data. 
Indeed, paradoxically, while the development of pharmaceutical 
products and the evidence standards required by the Food and 
Drug Administration (FDA) for product evaluation and marketing 
approval is driven by adherence to the scientific method, once a 
product is launched and claims made for cost-effectiveness and, 
in the case of ICER, modeled pricing and access 
recommendations, the scientific method is put to one side.  
Pseudoscience succeeds science. 
The rejection of a research program that meets the standards of 
normal science by groups such as ICER is best exemplified by the 
latest version of the Canadian health technology guidelines 
where it is stated: Economic evaluations are designed to inform 
decisions. As such, they are distinct from conventional research 
activities, which are designed to test hypotheses 33. While this 
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position puts modeled health technology assessment in the 
category of pseudoscience, it is also what may be described as a 
relativist position. Rather than subscribing to the position that 
the standards of normal science are the only standards to apply 
in health care decisions and value claims, the relativist believes 
that all perspectives are equally valid. Health care decisions are 
to be understood sociologically. No one body of evidence is 
superior to another. Results of a lifetime modeled simulation are 
on an equal basis with those of a pivotal Phase 3 randomized 
clinical trial. For the relativist, the success of a scientific research 
program, in this case one built on hypothetical models and 
simulations, rests not on its ability to generate new knowledge 
but on its ability to mobilize the support of the community. 
Basing decisions on models and simulations underpins the 
consensus view that evidence is constructed, never discovered. 
Instead of coming to grips with reality, science is about rhetoric, 
persuasion and authority 29. Truth is consensus. 
 
How is this consensus maintained?  The ISPOR consensus, 
embraced by ICER, on health technology assessment has been 
characterized in previous commentaries as a meme 34. This is 
deliberate, as it underpins the interpretation of ICER’s 
continued unqualified acceptance of the reference case as its 
core business model, as a sociological phenomenon. The ICER 
reference case which constructs evidence to support pricing 
and affordability pronouncements, can be characterized as the 
adoption of a unit of cultural transmission or unit of imitation; 
as an analog of gene pool propagation  ‘by leaping from body 
to body via sperm or  eggs’ 35. Human beings are good at 
imitation. The reference case meme appears to be adept in its 
infectivity, supported by an organizational infrastructure to 
defend it against competing views, ensuring survival through 
supporting propagation, longevity, fecundity (or acceptability) 
and copying fidelity. The spectacular adoption and propagation 
of this meme in seen in the health technology literature over 
the past 35 years with literally thousands of imaginary world 
technology assessments. Characteristically, few present claims 
that might be evaluated in, for example, the short term. Rather 
we are asked to believe in entirely imaginary constructs to drive 
formulary decisions. ISPOR is quite clear in its support for the 
reference case imaginary health technology meme: Leaders in 
the field of economic evaluation in health care have long 
recommended that analysts seeking to inform resource 
allocation decisions approximate the value of interventions in 
terms of incremental cost per QALY gained (emphasis added) 13.  
It’s not clear, with the imaginary constructs, how we might 
distinguish ‘approximate information’ from ‘approximate 
disinformation’. Is there some behavioral asymmetry in ‘losses’ 
‘vs gains’ that would have to be factored into such an 
assessment by a formulary committee?  
 
Models and Assumptions 
It is accepted that knowledge is provisional and permanently 
so. This stems from the obvious point that we can at no stage 
prove that what we ‘know’ is true. Attempting to believe or 
justify our belief in a theory is logically impossible. What we can 
do, by empirical assessment, is to try and demonstrate our 
preference for one theory over another (and apply it to the best 
of our knowledge).  
 
Constructing imaginary worlds which were never intended to 
generate potentially falsifiable claims cannot, therefore, be 
defended by an appeal to the ‘truth’ of their assumptions. If a 
health technology assessment claim is built upon a series of 
assumptions, a reasonable question is to ask what is the status 
of the various assumptions. Are they to be viewed as 
‘reasonable or ‘realistic’ metrics for an unknown future reality?  
Have they been selected from the literature because they seem 
appropriate? Are they the ‘best available’ from limited data? In 
the case of JAK inhibitors, the one-year model reflects the 
absence of data on long-term comparisons. ICER cannot defend 
a longer timeframe because it could not justify the assumptions 
required.  
 
More to the point, there is a belief that the fact that the 
selected assumptions are based, where feasible, on an 
empirical study validates the choice of assumption (e.g., 
network meta-analysis). For example, if the model is intended 
to incorporate utilities that have been reported in one or two 
studies (usually as few as that) for progression and time spent 
in the stages of a disease, then there is an immediate 
methodological issue. To claim that an assumption is valid is to 
revisit Hume’s induction problem (David Hume 1711-1776): an 
appeal to facts to support a scientific statement. Unfortunately, 
as Hume pointed out, no number of singular observations can 
logically entail an unrestricted general statement. Certainly, 
there may be comfort in reporting that ‘so far’ the claim that all 
swans are white has not been contradicted (until that Qantas 
vacation in Western Australia) so that one fully expects the next 
swan to be white. But as Hume pointed out, this is a fact of 
psychology and does not entail any general statement. From a 
utility perspective, the fact that one hundred papers have 
agreed (within limited bounds) generic utilities from the same 
instrument for a target population in a disease state stage is 
immaterial. We cannot secure this assumption: it cannot be 
‘established by logical argument, since from the fact that all 
past futures have resembled past pasts, it does not follow that 
all future futures will resemble future pasts’ 36. Claims, for the 
relevance of a constructed imaginary world built on the 
assumption that the model elements have been validated by 
observation is simply nonsensical.  
 
Despite ICER’s continued embrace, logical positivism is dead. It 
died some 80 years ago. All knowledge is provisional. Popper’s 
contribution was to make clear that Hume’s problem with 
induction can be resolved. We cannot prove the truth of a 
theory, or justify our belief in a theory or attendant 
assumptions, since this is to attempt the logically impossible. 
We can only justify our preference for a theory by continued 
evaluation and replication of claims. Constructing imaginary 
worlds, even if the justification is that they are ‘for information’ 
is, to use Bentham’s (Jeremy Bentham 1748-1832) memorable 
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phrase ’nonsense on stilts’. If there is a belief, as subscribed to 
by ICER, in the sure and certain hope of constructing imaginary 
worlds, to drive formulary and pricing decisions, then it needs 
to be made clear that this is a belief that lacks scientific merit. 
 
The ICER Reference Case 
Central to the ICER construction of imaginary value claims and 
the potential for many worlds is the reference case. Standards 
for model building, the construction of imaginary worlds, are 
clearly stated with the preference for imaginary frameworks 
that take a long-term or lifetime perspective. Value 
propositions are to be in imaginary cost-per QALY terms. Once 
an imaginary cost-per-QALY estimate (or estimates under 
different scenarios) has been constructed, the acceptability of 
a proposed product price is then assessed against cost-per-
QALY willingness to pay thresholds (typically $50,000, $100,000 
and $150,000 per QALY with exceptions for higher cut-offs for 
rare diseases). Whether a product ‘adds value’ is then 
determined in terms of its impact on an imaginary estimated 
lifetime modeled QALYs set against a proposed lifetime product 
cost where both are driven by constructed evidence.    
 
Over the past 30 years, literally thousands of imaginary 
modeled claims have been presented in the literature, including 
leading health technology assessment journals. Annual reviews 
of the status of cost-effectiveness or modeled claims in the 
three journals, Pharmacoeconomics, Value in Health and the 
Journal of Medical Economics found that the majority of models 
presented non-evaluable claims (typically lifetime cost-per-
QALY) 37 38 39 40 41. Where models were funded by a 
manufacturer a high proportion supported, in their modeled 
cost-per-QALY assessment, the manufacturer’s product. All too 
many of the papers were essentially marketing exercises 42 43.  
 
Despite the argument that the ICER reference case lacks 
credibility; that it is pseudoscience rather than science, there is 
little doubt that ICER will persevere. After all, if ISPOR persists 
in supporting, after a recent extensive membership review, the 
construction of imaginary incremental lifetime cost per QALY 
models to support formulary decisions (together with a gaggle 
of imaginary scenario offshoots of a base case model), ICER can 
continue to argue that it represents the ‘state of the art’ meme 
in presenting evidence reports from imaginary constructs.  
 
Manifest Score: Utilities and QALYs 
While apparently overlooked by ICER, ISPOR has published 
good practice guidelines for model builders to identify, review 
and apply health state utilities in cost-effectiveness models. 
Minimum reporting standards are proposed to judge the 
appropriateness of the utility metric selected. This good 
practice report was released in March 2019, which would have 
given ICER ample time to undertake such a review 44. As it 
stands, in the brief account given by ICER of the basis for its 
choice of health status utility metric for the JAK modeling EQ-
5D metrics, there is no mention of going beyond the material 
used in the earlier 2017 RA report.  
As an aside and, perhaps unsurprisingly, the ISPOR health state 
utilities good practice report did not raise the issue of 
fundamental measurement standards. Utilities or ordinal 
manifest scores were taken at face value and, for all intents and 
purposes, there was an implicit assumption that they had 
cardinal scales. Again, truth is apparently consensus. 
 
Too little attention is given in critiques by stakeholders and 
others of the ‘evidence’ to support model assumptions. In the 
latest evidence report, the key assumptions are listed in Table 
4.4 together with their rationale. While it is possible to apply 
sensitivity analyses to overcome specific uncertainties in 
assumptions (e.g., magnitude of HAQ rebound), in a number of 
cases ICER admits to an absence of robust published evidence 
(e.g., mapping of DAS28 to HAQ for the modeled treatment 
strategies; discontinuation rates) with a fallback on ‘expert 
opinion’. Even so, the point remains that the model is 
essentially a series of assumptions. As the revised modeling 
results for the JAK inhibitors makes clear, changing assumptions 
can change recommendations so that the prospect is for a 
series of modeled revisions as the ‘evidence base’ and ICER’s 
choice of assumption changes. At the same time, given the 
malleability of assumptions, it is of interest to note the ‘false’ 
precision with which the modeled results are presented. In the 
case of upadacitinib and adalimumab, ICER notes that ‘we 
found no difference in Lys (life-years) gained up to the fourth 
decimal place’ (pg. 55).   
 
Previous commentaries in this series have raised the concern 
that an unqualified use of the term QALY may give decision 
makers the impression that there is a common imaginary QALY 
standard that has been agreed to in health technology 
assessment 45. This is far from the case. ICER uses the term, 
almost indiscriminately, without qualifying its claims that the 
utility metric driving the QALY estimate is based on an often 
arbitrary choice of measure, typically involving a specific 
definition of HRQoL (defined by choice of health symptoms or 
dimensions and response level) rather than a broader concept 
of quality of life (QoL). If the intent is to mandate a specific 
generic utility metric, as recommended in the ICER reference 
case, then for US preference measures there are a number of 
options: EQ-5D-3L, EQ-5D-5L, SF-36, SF-12, SF-6D. Confusion 
can arise when, as in the RA evidence report, and in the earlier 
evidence report on TIMs, the ICER refers to the EQ-5D, without 
qualifying whether it is the 3-level or 5-level variant. Reviewing 
source documents referenced by ICER points to the 3-level 
variant. NICE in the UK is still struggling with the use of the 3- 
level as opposed to the 5L-level. While the 5-level is considered 
appropriate as a descriptive profile, there are ongoing concerns 
with the valuation of the 5-level 46. 
 
A point to note, however, is not just the limited number of 
responses open to patients within the health dimensions 
captured in the generic measure, but the limited ambit of those 
measures. Are these measures appropriate if the intent is to 
represent health related quality of life (HRQoL) in RA? The EQ-
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5D, for example, is based on five broad health dimensions: 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Patients respond: no problems, some 
problems and major problems. The SF-6D, by contrast, has six 
health dimensions (with levels of response in parentheses): 
physical functioning (6), role limitations (4), social functioning 
(5), pain (6), mental health (5) and vitality (4).  
 
Without going into details of each of the various preference-
based multi-attribute health status systems it is worth noting 
that the decision (if you insist on ordinal manifest scores) does 
matter, as the systems are far from identical. They differ in their 
coverage of health dimensions, in the defined levels, the 
description of these levels, the severity of the most severe level, 
the populations surveyed, the instruments used to determine 
the preference scoring and the theoretical approach for 
modeling the preference data into a scoring formula 47.  The 
same patients can have quite different scores depending on 
choice of instrument. But, of course our intent is to provide only 
‘approximate information’. To which might be added: none 
meet the required axioms of fundamental measurement.  
 
Interval Scales 
A further reason for describing the ICER reference case as an 
analytical dead end, rather than a path to discovery, is the 
failure to appreciate the importance of meeting the general 
axioms of measurement: invariance of comparisons and 
sufficiency 48. If these axioms are met then the result is an 
interval or cardinal scale. It is worth remembering Steven’s key 
observation in his seminal 1946 paper:  ‘With the interval scale 
we come to a form that is quantitative in the ordinary sense of 
the word’ 49 . 
Unfortunately, interval scores are not commonly found in the 
construction of imaginary worlds. Generic multi-attribute 
measures generate ordinal scores; the majority of patient 
reported (PRO) instruments generate ordinal scales. Indeed, it 
is not clear as to the extent, if any, that those developing 
generic multi-attribute instruments and clinically focused 
HRQoL instruments considered a latent construct and how this 
might guide instrument development to meet interval scoring 
or even ratio standards. 
General measurement theory recognizes four scales: nominal, 
ordinal, cardinal or interval and ratio. With ordinal scales the 
ranked response within an item ‘order’ is known but the 
differences between the responses is not. We may define a 
mode or median but not a mean. Cardinal or interval scales are 
where the order is known as well as the difference between 
responses on the scale. Interval scales open up a range of 
statistical options: means and standard deviations can be 
computed, change and effect sizes can be presented. However, 
with cardinal scales there is no ‘true’ zero. Ratios can’t be 
computed; there is no multiplication or division. It is only with 
a ratio scale, one with a true zero, that these are possible. As 
the QALY is a ratio, then a reasonable question is whether the 
‘utility’ measure (the denominator) should not only have 
cardinal properties but also the property of a true zero.  
 
Unless ICER can demonstrate that its choice of utility score and 
consequent QALY claims meet the axioms of fundamental 
measurement, then over and above the imaginary nature of the 
model, the cost-per-QALY claim lacks credibility in terms of 
fundamental measurement. Decision makers might accept the 
notion of ‘approximate information’; it is unlikely they would 
accept measures within the ‘approximate information package’ 
that lacked mathematical credibility. 
Patient Centric Outcomes 
PRO instruments such as the EQ-5D-3L support the more 
narrow and clinical concept of HRQoL. Typically, HRQoL 
measures do not capture the patient voice. They capture, as in 
the case of the EQ-5D, the interest of the treating physician in 
assigning health symptoms or dimensions with ordinal 
response levels within dimension. This is combined with time 
spent in health state clinical stages to create QALYs. Patient 
preferences are absent; the preferences are those of a 
community sample where only a handful of respondents will 
have had any experience of specific disease states, their natural 
history and impact. The QALY measure is, of course, 
meaningless. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
If we consider the perspective of the patient, a more 
appropriate framework is to put HRQoL to one side and 
consider the QoL of the patient. The question we might 
consider is whether the patient’s needs are fulfilled. The needs 
model, developed in the 1990s, hypothesizes that the value of 
individual lives is dependent on the extent to which their human 
needs are fulfilled.  Value is low when few needs are met 14 18.  
Certainly, the impact of treatments within a disease state can 
be captured by health symptoms and response defined within 
a HRQoL model, but these are only sufficient as an index of the 
clinical or operational impact of interventions as reported by 
the patient or perceived by the treating physician for a selected 
symptom set. The functional status of a patient is impacted by 
more than symptom resolution. There is a range of possible 
other influences such as social support, family assistance 
finances, and education. HRQoL raw scores may ‘improve’ while 
failing to meet the needs of the patient 18. At the same time, 
providing closer social support may improve needs fulfillment 
but may not register as a HRQoL improvement. 
 
If we are to develop a patient-centric outome (PCO) needs-
based measure, then we have to begin with the patient. This is 
achieved by a ‘bottom-up’ commitment to qualitative 
interviews with patients to ask how the patient’s life has been 
affected by the disease in question, and probe how limitations 
of functioning affect the interviewees 14 18. This is the first step 
to providing, within a Rasch modeling framework, statements 
regarding needs fulfilment, issues common to the target patient 
group and ultimately the final item set.  
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If a manufacturer is to make a needs-based case for its product 
it is not enough to focus on a ‘top down’ HRQoL instrument. 
Assessments by third parties such as ICER to assess the ‘value’ 
of the intervention miss the point. It is the ability to measure 
response defined in needs fulfillment terns, not attempts to 
draw inferences from a partial and possibly misleading, 
clinically focused HRQoL measure that is claimed to support the 
value case. This does not mean that it is not possible to 
construct a generic needs measure, such as the Nottingham 
Health Profile developed in the late 1970s 50. Rather, our focus 
should be on disease specific patient centric outcome (PCO) 
measures if we wish to evaluate therapy response claims   . 
 
Rasch Measurement Theory 
The first step in the development of an instrument, a PCO 
rather than a PRO instrument, is agreement on a unifying 
construct or attribute set. A latent trait or construct is 
unobservable; what our primary task should be is the 
construction of a PCO that meets Rasch standards. Given the 
construct, responses to locally independent items are 
observable manifestations of those internal but unobservable 
attributes. If our construct is needs-based QoL, as the measure 
of benefit to the patient of a new therapy, then the presence 
and amount of the latent trait has to be operationalized, or 
inferred, from item responses. To illustrate this point, Bond and 
Cox give the example of temperature 17 . As a latent construct, 
temperature cannot be observed directly, we can only assess 
the effects of temperature changes on certain classes of objects 
(e.g., the volume of mercury in a carefully calibrated and 
constructed space). The thermometer is, importantly, 
unidimensional and we read off temperature by a calibrated 
scale that has cardinal or interval invariance properties. This is 
what we must achieve in the assessment of QoL as a needs 
construct in therapy impact; not an ordinal HRQoL scale that 
lacks a coherent construct. It is important to note also that 
while the term ‘measure’ is often applied to the Rasch 
construct, the score is actually counts of discrete observations. 
The raw score is the sufficient statistic for that person in 
quantifying QoL. 
 
Fundamental measurement is central to the Rasch model. As 
first conceptualized, the object was to apply the standards of 
measurement common to the physical sciences to construct 
fundamental measures: interval level measurement. The Rasch 
model is confirmatory; it requires the data to fit the model 17. If 
this is achieved, then we can claim that the instrument 
conforms to a scale with invariant, interval measurement 
properties generating a single score. Our role, therefore, is to 
identify a set of items that satisfy the Rasch model. Retention 
and exclusion of items is a key issue, together with the 
application of the tools of classical test theory (CTT) to assess 
face and content validity together with assessments of the 
reliability and validity of the final item set.  
 
While, as noted, Rasch fits the data to the model; conventional 
modeling fits the model to the data. In the case of EQ-5D utility 
scores, these are generated by an algorithm that is designed to 
ensure preference weighted responses to the HRQoL items to 
fit a utility scale (range 0 = death; 1 = perfect health). This is 
required to create QALYs (dividing time spent by the utility of 
that interval). Users implicitly assume in the reference case that 
the EQ-5D and other generic measures (and for the majority of 
disease specific patient reported outcomes (PRO) instruments) 
that the scale has cardinal rather than ordinal properties.  This 
means a response from 0.4 to 0.5 is the same interval as 0.7 to 
0.8). This, unfortunately, is not the case: the instruments utilize 
an ordinal calibration. This occurs because the issue of 
unidimensionality in instrument development has been 
ignored. Certainly, the instrument may claim to meet the 
standards required in classical test theory (CTT) but they fail to 
provide valid means and standard deviations, requiring non-
parametric statistical analysis for evaluation. More formally, we 
require a mechanism for translating manifest to latent scores: 
this is achieved by Rasch analysis that delivers conjoint 
measurement when the data fit the model 16 51. 
 
The key features, therefore, of Rasch analysis, which unifies 
measurement issues required for interval scaling is where a set 
of questionnaire items are to be summed to provide a total 
score. This involves testing for: 
 
 Internal construct validity of a scale for unidimensionality 
which is required for a raw summed score 
 Item invariance for interval level scaling 
 Appropriate category ordering 
 Differential item functioning 19 20 
 
Unidimensionality and Rating Scales  
‘A basic assumption of rating scales is that their items measure 
a common underlying construct. If this can be demonstrated 
then the scale is unidimensional; if not the scale is invalid. This 
is a critical standard for modeling. Hypotheses must be 
presented as unidimensional. We cannot assume 
unidimensionality. Even in the construction of an imaginary 
ICER-type world, unidimensionality has to be demonstrated not 
assumed. If value claims are made, then the measures must 
allow change in scores to be interpretable. The issue with 
HRQoL ‘measures’ is that they were not developed from an 
underlying QoL construct. Their composition (choice of items) 
reflects the decision of clinicians, with preference determined 
by the community rather than the patient.  
 
If we accept the need for a coherent construct such as needs 
based QoL then we have a firm base to guide instrument 
development and the construction of an instrument that has 
the required unidimensional properties. There is no common 
ground with either multi-attribute utility scores or the CTT 
based PRO measures. Claims that, under certain circumstances 
and with appropriate minor adjustments we can 
‘unidimensionalize’ such instruments are simply beside the 
point. We need a common and defensible construct that is 
applicable across specific disease areas in a representative 
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target population. In other words, for a unidimensional Rasch 
scale we require a spread of items ordered for difficulty and a 
distribution of abilities among respondents to respond to those 
items. With few exceptions, unidimensionality cannot be 
inferred ex post, it has to be demonstrated for item order and 
item fit as the instrument is developed. 
 
Rasch analysis has been applied widely in developing 
instruments for assessing therapy response over the past 30 
years. Apparently, ICER (and ISPOR) did not receive the memo. 
Or, to be possibly more reasonable, they took on faith the 
mandatory requirement by the National Institute for Health 
and Care Excellence (NICE) in the UK for the EQ-5D -3L in their 
reference case requirements. However, RMT is now effectively 
the standard for creating and evaluating measurement 
instruments 20.  Given this, ICER has an interesting (and 
impossible) task  to demonstrate both globally and, in this case, 
for the JAK inhibitor target population that its selected outcome 
measures, while not patient centric, meet required instrument 
standards for fundamental measurement and that this 
‘measure’ and not a patient centric needs based QoL 
instrument is the appropriate outcomes measure.. 
 
Once the requirement for RMT in instrument development is 
recognized, with the construction of unidimensional cardinal 
scales (not utilities) ICER in the absence of other supporting 
evidence is in an awkward position. It can either go ahead and 
continue with its reference case model (‘not perfect but others 
do it’) or propose an alternative framework to meet the 
objectives of its business model. This is a daunting prospect. 
ICER will not only have to admit that its previous evidence 
reports that propose modeled claims for pricing and access, 
including those for RA, are  mistaken (and misleading) but that 
they represent a methodology that fails to meet the standards 
of normal science. Put simply: incremental cost per QALY claims 
and thresholds are redundant. This, of course, is unlikely to 
happen 
 
Standing by Generic Utilities 
If the decision by ICER is to carry on in the sure and certain hope 
that the many worlds claim will escape close scrutiny in the 
absence of accepted measurement standards for 
unidimensionality and interval scoring, then ICER has to take on 
board ongoing debates for utility scores and the choice of an 
acceptable instrument. It is incumbent upon ICER to undertake 
a systematic review of the application of the measures in RA, 
with particular focus on the target JAK population, to identify 
relevant studies. It is not acceptable, according the ISPOR good 
practices to rely, as ICER does, on only one or two studies. 
Rather, the recommendation is for a synthesis of published 
health state utilities for a given health state. If this is impossible 
due to a limited number of studies, the model builder might be 
well advised not to press forward.  
 
As well as issuing good practice guidelines for health state 
utilities in imaginary cost-effectiveness models, ISPOR has also 
released good practice guidelines for mapping from non-
preference based outcome measures for those attempting to 
model health state generic utilities (January 2017) 52. Again, 
with sufficient time, it would have been incumbent on ICER to 
apply these guidelines to support the choice of mapping 
algorithm, its quality and relevance. This, unfortunately, is not 
the case.  The RA mapping function is presented with little 
justification for its application, relying on a limited and 
somewhat dated evidence base.  The mapping technique used 
in the ICER report for JAK inhibitors is identical to that used in 
the earlier evidence report on Targeted Immune Modulators 
(Table D6) 53. The comments made in respect of the former 
apply equally to the latter, which should give pause as to the 
merits or otherwise of the earlier ICER recommendations for 
pricing and product access. 
 
In the absence of a systematic review of health status utility 
scores and mapping functions for target patient RA populations 
appropriate to the introduction of JAK inhibitors, it is not clear 
why ICER persists with the EQ-5D-3L in modeling imaginary 
worlds.  The EQ-5D-3L and EQ-5D-5L are, to all intents and 
purposes, separate systems. ICER should make quite clear that 
it is not the EQ-5D-5L utility values that are being estimated but 
utility values for the EQ-5D-3L. ICER should not think it can use 
these metrics indiscriminately in the same model nor, as it has 
done with oral semaglutide use EQ-5D-3L and HUIMk3 utilities 
in the same model with the rather disingenuous excuse that 
they give similar scores 54. 
 
ICER, in fact, is in a similar bind to NICE in the UK in the choice 
of mapping algorithm and the presence of two versions of the 
EQ-5D. If there is to be a level imaginary playing field for 
comparing imaginary products value claims over time in a 
defined target population within a disease state such as RA, or 
for comparisons between disease states then, ICER must adopt 
not only a standard mapping algorithm (e.g., mixed method) to 
create a preference-based score for modeling, but it must also 
mandate the preference-based outcomes instrument that will 
be utilized for all evidence report modeling. If these 
requirements are not met then ICER will face criticism that its 
willingness to pay thresholds must be re-calibrated for the 
mapping technique utilized and the choice of target utility 
values. If two utility metrics are used in the same model then to 
present the same price discounting recommendation with 
different cost-per-QALY willingness of pay thresholds calibrated 
to the two metrics is problematic. The issue becomes even 
more problematic when different models employ different 
frameworks for time spent in different disease states and then 
different estimates of costs.  
 
If ICER decided to mandate the EQ-5D-5L utility values for the 
reference model to construct imaginary worlds, then it would 
have to re-calibrate previous studies in order to ensure that the 
evidence based for QALY claims was consistent. In this respect, 
two recent studies are worth noting. The first of these studies 
evaluates the relationship between the EQ-5D-3L and the EQ-
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5D-5L to consider what effect this has on cost-effectiveness 
claims in RA 55. Applying best-fitting models the authors found 
that the mapping coefficients for the modelling and the latent 
factors were significantly different. Overall, the 5L shifts ordinal 
utility values towards full health and compresses them to a 
smaller ordinal range so that improvements in quality of life are 
valued (ranked) less. This results in substantially different 
estimates of cost effectiveness. In the second evaluation, the 
focus is on the impact of moving from the EQ-5D-3L to the EQ-
5D-5L in NICE appraisals, estimating 5L utility vales from 21 
comparisons of interventions 56. The authors concluded that 
the two measures of utility value lead to substantially different 
estimates of incremental QALYs and cost-effectiveness 
(without any discussion of fundamental measurement axioms).   
 
Of particular interest is a recent study modelling the 
implications of a switch from the EQ-5D-3L to the EQ-5D-5L not 
least because it is focused on evaluating drug therapies in 
rheumatoid arthritis 57 . As the authors point out, the switch to 
the EQ-5D-5L version of the original instrument was prompted 
by concerns over the sensitivity of the instrument and 
floor/ceiling effects; but not to its fundamental measurement 
properties. Although mapping or crosswalking between 
instruments (inputs to outputs) is popular, the authors caution 
against conditional modeling (e.g. a regression model) mapping 
from one measure to the other even when they are captured in 
the same data set. Reasons given are  (i) utility scores have 
highly irregular distributions and mapping methods often fit 
poorly; (ii) use of a single utility score loses the additional 
information in the dimensions of response; and (iii) the direct 
comparison approach is necessarily specific to the particular 
scoring system making it difficult to explore sensitivity to 
scoring system variations. The approach taken by the authors is 
‘response mapping’ which considers the statistical relationship 
between the 3L and 5L responses but with the utility score 
brought in at the final analysis stage. 
 
This last assessment of the impact of alternative mapping 
functions including valuation algorithms for the two versions of 
the EQ-5D utilizes the US National Data Bank for Rheumatic 
Diseases (NDB) which captured both versions of the EQ-5D in 
the January 2011 wave when the NDB switched from the EQ-
5D-3L to the EQ-5D-5L versions. Two features of the analysis are 
important if we consider the ICER reference case. First, 
comparing the EQ-5D-5L and the EQ-5D-3L when the two are 
captured in the same data set and second, the options for 
mapping from the EQ-5D-3L to a ‘revised’ utility score based on 
the EQ-5D-5L. In the former case, there are significant 
differences between the descriptive systems where the two 
instruments give ‘significantly different pictures of the 
relationship between individual health states and their 
demographic and clinical determinants in respect of mobility 
and pain dimensions’. Mapping between health states before 
applying utility scores can provide a robust framework for 
converting old 3L evidence to a 5L basis. Direct mapping 
between utility scores requires a sufficiently flexible model. 
Even so, as this conflates the effect of the redesigned 5L health 
description and the revised utility tariff ‘it does not offer a 
natural way of comparing alternative utility tariffs’. Finally, in a 
re-examination of a trial of combination RA drug therapies 
switching from the 3L to the 5L can make ‘a substantial 
difference to the conclusions from cost-effectiveness studies’.  
 
To illustrate the impact of moving from theEQ-5D-3L to the EQ-
5D-5L the authors consider cost-effectiveness claims based on 
the 2-year CARDERA trial. Estimating the EQ-5D-3L directly from 
the trial data  for methotrexate (MTX) as monotherapy yields 
an estimated total QALYs of 1.24 with estimated incremental 
cost-effectiveness compared to MTX+ciclosporin (CS)  of £4,648 
and £13, 714 for MTX+prednisolone (PNS). When the EQ-5D-5L 
is mapped from the EQ-5D-3L trial data utilizing a limited 
covariate set yields an estimated 1.54 QALYs and an ICER MTX 
vs. MTX+CS of £6,755. In a second model the covariates are 
reintroduced but with an assumption of independence across 
health domains. This yields an estimated 1.437 QALYs with an 
incremental cost effectiveness ratio of £6,054 for MTX vs. 
MTX+CS and £15,137 for MTX vs. MTX+PNS.  
 
A Multiverse of Imaginary Worlds 
Although ICER recognizes that the modeled claims from the 
2017 evidence TIM report should not be compared to those for 
the 2019 JAK inhibitors evidence report, this is symptomatic of 
a wider problem.  With ISPOR and its acolyte ICER’s embrace of 
the imaginary technology assessment meme, any numbers of 
models can, and have been developed within disease areas 
ostensibly to address the same question of lifetime claims for 
cost-effectiveness for specific therapies and the apparent value 
that these confer on the target treating population. 
Understandably, this creates confusion not only in respect of 
the diversity of modeled outcomes that utilize the same metric 
but the diversity of outcome metrics that are claimed to 
represent the ‘true’ measure of value. All would or could claim 
that they subscribe to the technology assessment meme and 
that they recognize the reference case framework. While it 
might not be clear whose value (physician, patient, insurer, 
health system) a model represents, the model builder can press 
forward in the sure and certain hope that the claims made will 
escape any scrutiny. The claims are ‘for approximate 
information only’ and are not intended, as detailed above, to 
meet standards for empirical credibility, evaluation and 
replication in treating environments. Claims will not be 
deconstructed; they will be taken at face value. 
 
Onward to Imaginary Treatment Pathways 
For those committed to the ISPOR/ICER heath technology 
meme, a logical next step is to consider treatment pathways 
within an expanded imaginary framework. As these pathways, 
involving both sequential and polypharmacy are complex, a 
characteristic of chronic diseases where RA is an exemplar, 
creating a framework to indulge the multiplicity of options 
could be seen as a ‘useful’ next step. Although it is early days 
before we witness a ‘torrent’ of treatment pathway imaginary 
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models, a simulation model IVI-RA has been developed to 
assess the value in RA of treatment sequence strategies 5 6 7.  
 
The IVI-RA model, which is an open source on-line resource, 
attempts to capture, through the creation of user-defined 
assumptions and constructions of multiple imaginary worlds, 
the effect of patient histories on therapy impact and the 
variation of those outcomes across patients. In its present 
incarnation the imaginary IVI-RA open source model is intended 
to provide an assessment of the value of sequential treatment 
strategies for those with moderate to severe RA who have not 
responded to conventional disease modifying  antirheumatic 
drugs (cDMARDs) and who are naïve to biologic DMARDS 
(bDMARDS) or JAK/STAT (signal transducers) and inhibitors. 
 
The model is a discrete time simulation with a 6-month cycle 
containing some 384 possible model structures and 
assumptions ‘informed by previously published models’ (i.e., 
previously constructed imaginary worlds). Presumably, not all 
of these model structures would be presented at the same time 
for a health system for review. The principal purpose of the 
model, which adopts an analog to the ICER reference case 
imaginary lifetime modeling framework, is to assess the impact 
on the IVI-RA assumed value criteria (the EQ-5D-3L) of the 
impact of parameter uncertainty, structural uncertainty and 
model perspective. Fundamental measurement does not 
appear to be an issue. The view taken is entirely consistent with 
the health technology meme: it is to inform decisions in order 
to ensure (or assist?) in efficient health care decisions.  
 
The principal rationale for the IVI-RA is to overcome issues of 
model access and lack of transparency through an open source 
iterative collaborative approach to building imaginary worlds in 
RA. It is proposed to value alternative treatment pathways over 
the lifetime of a target cohort of RA patients allowing both cost-
effectiveness analysis claims as well as multiple criteria decision 
analysis (MCDA). For each treatment sequence selected, the 
imaginary IVI-RA framework will, for selected time horizons 
generate the following outcomes: progression of disease 
severity (HAQ scores); time to treatment discontinuation; 
remaining life expectancy; QALYs; health sector costs and 
productivity losses. Issues of credibility of claims, evaluation 
and replication are apparently not relevant. 
 
The authors envisage that the IVI-RA model will be continually 
updated as new studies provide sufficient data, agreed to by an 
expert panel, to change the assumptions driving the simulation 
model. This is seen as a necessary step in the evolution of 
imaginary worlds to counter the  once-upon-a time feature of 
the overwhelming majority of published imaginary worlds 
where the model is held by the author with little if any chance 
of being updated. The open source framework for the IVI-RA 
model allows this process of ‘continuing revolution’ with 
presumably a  continuing succession of updated models 
generating a budding-off cascade of ‘new’ scenarios to be 
presented to decision makers ad infinitum. The underlying 
structure of the model will, presumably remain the same with 
QALYs re-generated from new studies embodying the EQ-5D-3L 
generic instrument to re-create lifetime incremental ‘manifest 
score’ cost-per-QALY claims. The patient voice is ignored.  
 
It is recognized, not surprisingly, that the IVI-RA can generate 
multiple competing model structures with a given set of 
assumptions, with assumption modifications such as mortality 
having large impacts on QALYs and incremental QALY 
differences (and presumably) on pricing recommendations if 
threshold willingness to pay criteria are introduced). Clearly, 
there needs to be a winnowing process to identify which of the 
imaginary constructs is expected to be most ‘realistic’ in 
projecting the hypothetical RA population’ treatment pathways 
forward for 10, 20 or 30 years. One suggestion is some form of 
‘averaging’ over the competing imaginary worlds to simplify 
information claims. These issues are expected to be addressed 
(i) through research, debate and collaboration and (ii) model 
averaging techniques to ‘properly capture structural 
uncertainty’. The authors also propose the option of expected 
value of perfect information techniques to identify the most 
sensitive parameters. It is puzzling that so much attention 
should be given to what is after all an imaginary construct that 
fails the standards of normal science; a model framework that 
sets the initial condition for a multiverse of imaginary worlds 
(c.f., quantum decoherence, many worlds and the absence of 
waveform collapse). 
 
Without revisiting earlier assessments of the ICER reference 
case, it is clear that the IVI-RA model suffers from exactly the 
same fatal flaws. It is, one again, pseudoscience. It is to be 
hoped that resources are not being devoted to emulating this 
framework in other disease states. 
 
Needs Fulfilment in Rheumatoid Arthritis 
If the references cited in the final evidence report for JAK 
inhibitors are an indication, ICER is either not interested or 
unaware of the amount of instrument creation, following RMT 
standards, which has occurred in RA over the past 25 years. 
Perhaps they again missed the memo. This may be because 
patient centric measures are of no interest or that ICER is simply 
unaware of the importance of measurement in therapy impact 
claims. The closest ICER comes to recognizing patient needs in 
RA is to review briefly the recent Radawski et al survey of unmet 
medical need in RA and to report on discussions with patients 
and patient organizations. 58. As ICER notes from these surveys, 
only a minority of patients reported satisfaction with their 
treatment with ICER noting that ‘much work remains to be done 
on quantitative, patient centered measures of treatment 
success’ (pg. 10);’. Perhaps, once again ICER (and patient 
organizations) have failed to receive the memo that disease 
specific needs fulfillment QoL proposals had been in press for 
the past 40 or more years. Indeed, it is worth noting that much 
of the debate over the appropriateness of QALYS for particular 
patient groups (e.g., older persons, those with disabilities, 
persons with rare diseases) can be put to one side once the 
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QALY is abandoned. The issues can be accommodated with a 
needs-fulfillment disease specific PCO. 
 
The first of these instruments is the Rheumatoid Arthritis QoL 
(RAQoL) instrument developed in 1997 59. A further four 
rheumatology instruments were published over 10 years ago. 
The motivation behind the RAQoL was that with the increasing 
number of multinational clinical trials in RA, a measure was 
necessary, in a range of language versions (presently 33), that 
‘is derived from the experiences of RA patients’. The theoretical 
basis for the model is that, from a needs perspective ‘life gains 
its quality from the ability and the capacity of the individual to 
satisfy his or her needs’.  
 
The RAQoL was the first patient centric quality of life 
questionnaire in RA. It is also distinct from other questionnaires 
to include physical contact as a dimension together with 
capturing activities of daily living, social interaction/function, 
mood and recreation and pastimes. The RAQoL has 30 items 
with yes/no response 60. The first five ordered items are: 
 
 I have to go to bed earlier than I would like 
 I’m afraid of people touching me 
 It’s difficult to find comfortable shoes that I like 
 I avoid crowds because of my condition 
 I have difficulty dressing 
 
As a recent review notes, the RAQoL has excellent psychometric 
properties and measuring ‘the impact of RA and its treatment 
from the patients perspective (emphasis added), [makes] it 
suitable for determining the value patients gain from 
interventions’ 61. 
 
The RAQoL is of particular interest as it is only one of the Galen 
instruments in RA that are designed to capture the patient 
voice. Since 2000, Galen Research PCO instruments have all 
been developed using the RMT standards. The other 
instruments develop by Galen Research in rheumatology 62 are:  
 
 Ankylosing Spondylitis Quality of Life Measure (ASQoL) 63 
 Osteoarthritis Quality of Life Measure (QAQoL)64 
 Psoriatic Arthritis Quality of Life Measure (PsAQoL)65 
 Systemic Lupus Erythematosus Quality of Life Measure 
(LQoL)66 
 
Importantly, the RAQoL has been used as an exemplar for the 
application of RMT to developing patient-centric models (again 
some 13 years ago) 67 .  Also, given the timeframe for the ICER 
final evidence report it might be worth noting that the 
McKenna et al seminal papers on patient value and the needs 
fulfillment construct for RMT were first published in 2004, in 
the ISPOR journal Value in Health, with a further set published 
in the Journal of Medical Economics in 2018/19. 
 
 
Response to Public Comments 
Before asking for public comment from stakeholders in RA, it 
might be useful for ICER to point out that their reference case 
methodology fails to meet standards for credible, evaluable and 
replicable claims that capture the value of competing therapies 
for patients. More to the point, ICER should also point out that 
their incremental cost-per-QALY projections, while ‘state of the 
art’ fails the required measurement properties for interval 
scores even within the imaginary reference case framework.  
 
If ICER admits that it is utilizing measures taken from the 
literature on utility metrics in RA that lack logically defensible 
measurement properties and that its cost-per-QALY claims lack 
merit, then it needs to defend its choice of metric and model 
and explain why patient centric measures such as the RAQoL 
which meet criteria for both relevance to the target patient 
population and unidimensionality are ignored. It is not 
sufficient that in its defense of QALYs to say that: ICER believes 
that the QALY is highly useful and informative measure of 
patient outcomes with a broad context and long-standing 
application.  Importantly the QALY reflects patient preferences 
for health states in a consistent and evidence based manner…68. 
Apart from the fact that the ICER in its advocacy of a generic 
QALY does not address the question of whether or not the 
needs for patients in the target RA patient group are being 
captured, the ordinal measurement characteristics of the EQ-
5D do not in fact reflect ‘patient preferences’ and certainly not 
in a ‘consistent’ manner. What is overlooked is that the patient 
responses for the EQ-5D-3l are weighted by community 
preferences; the manifest score is not the utility of patients in 
the target RA group, but the community valuation of the 
responses to the limited symptoms captured by physician 
choice in the EQ-5D-3L which may bear no resemblance to 
patients’ needs. 
 
Of course, it might be argued from a ‘health care central 
planning’ perspective that we have to apply community 
preferences across the board to make value claims for pricing 
and access in RA. This begs the questions of: (i) whose 
preferences in the ‘community’ and (ii) which utility system. 
Perhaps the community might also be canvassed on the 
importance of meeting fundamental measurement standards 
in value assessment. 
 
It is also worth noting ICER’s standard response to public record 
comments on the choice of a one-year model:  As stated in the 
report, we chose to model these treatments over a one year 
time horizon due to the uncertainty surrounding the long-term 
impact of these drugs, the number of subsequent lines of TIMs 
and if and when patients transition to palliative. Even with this 
limited evidence base (and speculative use of assumptions), 
ICER still feels it is in a position, presumably in its role of arbiter 
of the ‘public interest’ to announce: Our evidence review 
suggests that upadacitinib is modestly more effective than 
adalimumab, whereas the evidence cannot demonstrate added 
effectiveness for tofacitinib, and we found no evidence with 
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which to compare baricitinib to adalimumab. Policymakers will 
need to consider how to judge the value of a new treatment 
when its direct competitors are not fairly priced to begin with 69. 
The notion of ‘not fairly priced’ being driven by the construction 
of a one-year imaginary world with utility estimates based on 
an unsupportable ordinal calibration. 
 
Affordability 
Although a therapy may meet ICER’s arbitrary willingness to pay 
thresholds for cost-effectiveness as determined by the 
imaginary modeled construct, this first hurdle may be 
surmounted only to be halted at the second hurdle: ICER’s 
potential budget impact threshold. 
 
In May 2019 ICER determined that the annual budget impact 
threshold for each individual new molecular entity would be 
$819 million. If projected annual US spending on a specific drug 
exceeds this threshold then ICER will determine the maximum 
number of eligible patients who would be able to receive the 
therapy, at multiple possible pricing points (lower than the 
price deemed cost effective in the first hurdle analysis) without 
exceeding the threshold.  
 
The final evidence report concludes that the JAK inhibitors 
budget impact falls within this arbitrary ceiling. Whether 
anyone should take this back-of-the-envelope rationing alert 
seriously, is a moot point. To recommend a ceiling for patient 
access to meet a notional budget threshold put to one side 
assessed clinical benefits and needs fulfillment for the 
individual patient, and whether this merits additional funds 
being allocated, as well as potentially creating waiting lists for 
access. It is all well and good to recommend prior authorization 
but without recommended criteria for approval/refusal, it is a 
hollow recommendation. After all, it would be presumably 
possible to translate the aggregate budget limit into imaginary 
QALYs and estimate the allocation of these QALYs to each 
molecular entity and estimate the number of patients allowed 
to utilize the therapy! Unfortunately, this would raise the 
question again of why imaginary generic QALYs are used when 
the focus is presumably (again) on the benefits and harms to 
patients. 
 
Conclusions 
If our understanding of therapy response and the development 
of guidelines to support evidence based decision making in 
health care  is to advance then it has to be through the 
application of the scientific  method to discover new facts; a 
process, through hypothesis testing, of conjecture and 
refutation. Science does not advance through constructing 
medieval imaginary worlds or subscribing to a meme that 
believes truth is consensus. It is difficult to accept that claims 
created by reference case models with time horizons of 10, 20 
or 30 years that lack scientific merit should be taken seriously.  
Nevertheless, ICER perseveres. This is, of course, supported by 
the absence of any attempt to generate credible and evaluable 
claims as a basis for a non-imaginary understanding of the 
contribution of JAK inhibitors to the progression of RA. As noted 
in previous commentaries, constructing imaginary worlds is an 
analytical dead end. This stands in contrast to the commitment, 
in many countries, to the role of RA patient registry platforms. 
One example is the Swedish BARFOT study and its links to 
national registries to capture comorbidity and mortality data 70. 
If therapies such as the JAK inhibitors are to be evaluated then, 
rather than constructing imaginary worlds to drive formulary 
decisions resulting in ‘approximate information’ 
recommendations for limited access for patients to novel 
therapies, we should consider research platforms. These have 
the potential to provide a meaningful framework for assessing 
clinical impact as well as options for RA specific HRQoL and QoL 
needs-assessments with feedback to formulary committees in 
real time 71. This is the approach proposed in the Minnesota 
formulary guidelines published in 2017 72.  
 
Our resources in time and effort would be better employed in 
tracking the impact of JAK inhibitors, or any other RA therapy, 
in treatment practice both to evaluate and replicate pivotal RCT 
claims but also to extend this to assessment for the impact of 
JAK inhibitors on PCO measures. Measurement is integral to 
this. The RAQoL has some 25 years of application in clinical 
practice. If we are concerned with JAK inhibitors and patient 
value this should be our reference point, not a smorgasbord of 
modeled scenarios from an on-line computer game that 
expressly excludes patient value and fails to meet required 
measurement standards.  
 
As detailed in this commentary and in previous commentaries 
on ICER’s reference case methodology, the approach taken by 
ICER in constructing imaginary worlds to support pricing 
recommendations fails to meet the standards of normal 
science. The approach should be seen as pseudoscience and 
any conclusions reached subject to this caveat. The fact 
remains, and ICER implicitly acknowledges this in its 
reformulation of its ‘house model’, there is a potential 
multiverse of RA models, to include competing models for JAK 
inhibitors. This is shown in the ICER review of the RA model 
literature. In practice, you choose your timeframe, the model 
structure and the assumptions to drive your conclusions.   
 
The potential for a multiverse of models is further enhanced by 
the need to apply utility values to create cost per QALY claims. 
In common with other generic utility instruments, the EQ-5D 
does not meet required cardinal measurement standards. It 
also, in common with other instruments, puts to one side any 
claim to be a patient centric instrument. If we are to assess the 
impact of competing therapies in RA then we need to forget 
operational symptom and functioning HRQoL instruments 
which lack a coherent latent construct to those patient centric 
instruments which have a coherent needs-based QoL construct. 
 
The question that is of most concern is whether or not ICER (and 
IVI-RA) will take note of the criticisms advanced here. If the end-
game is to provide a ‘take our word for it’ price discounting and 
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affordability media release, then issues such as the appropriate 
measure of patient value that meets RMT criteria are beside the 
point. After all, we can safely assume that few in the audience 
will delve any deeper than the final recommendations. Indeed, 
from a global perspective there is a health technology 
assessment industry devoted to exercising its imagination in 
cost-effectiveness claims. Whether it is possible to convince 
advocates that the ‘emperor has no clothes’ is questionable 
given their long-term commitment of ISPOR and others to this 
meme and their ongoing success in enforcing meme 
transmission fidelity. 
 
In the absence of a commitment by ICER to the standards of 
normal science, ICER can expect continued criticism of its 
modeling claims by manufacturers and other interest groups 
pointing to failure of ICER to meet the standards of normal 
science. If the focus on imaginary ‘approximate information’ 
constructs is seen as the gold standard this merely underscores 
the point that not only can competing models be built, but that 
it is always possible to ‘reverse engineer’ a model to achieve a 
‘supportive’ cost-effectiveness claim. Certainly, the various 
models can be viewed as providing ‘approximate information’ 
as well as ‘approximate disinformation’; the problem is the 
impossible task of distinguishing one from the other. 
 
It is unclear what decision makers are to conclude in the 
prospective deluge of competing and conflicting claims for 
preference weights, utility metrics and cost-effectiveness: 
drowning in information yet thirsting for knowledge. As a 
recent opinion piece in the New York Times commented: But 
the internet is as good a tool to restrict free speech – to flood 
the zone with so much low-quality information that the 
marketplace of ideas becomes landfill where it’s impossible to 
separate the good from the garbage 73. 
 
 
 
Conflicts of Interest PCL is an Advisory Board Member and 
Consultant for the Institute for Patient Access and Affordability, 
a program of Patients Rising. 
 
 
 
 
 
References  
1 ICER. Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value. Draft Evidence Report. September 26, 2019 
https://icer-review.org/wp-content/uploads/2019/03/RA_Working_Draft_Report_PUB2.pdf  
 
2 ICER. Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value. Draft Evidence Report. October 11, 2019 
https://icer-review.org/wp-content/uploads/2019/03/ICER_RA_Draft_Evidence_Report_101119.pdf 
 
3 ICER. Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value. Evidence Report.  26 November 2019 
https://icer-review.org/wp-content/uploads/2019/03/ICER_RA_Evidence_Report_112619.pdf 
 
4 ICER. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value. Final Evidence Report and Meeting 
Summary. 9 January 2020 https://icer-review.org/wp-
content/uploads/2019/03/ICER_RA_Final_Evidence_Report_and_Meeting_Summary_010820.pdf 
 
5 Incerti D, Curtis J, Shafrin J et al. A flexible open-source decision model for value assessment of biologic treatment for rheumatoid 
arthritis. Pharmacoeconomics. 2019;37:829-43 
 
6 Jansen J, Incerti D, Curtis J. Toward relevant and credible cost-effectiveness analyses for value assessment in the decentralized US 
health care system. J Managed Care Special Pharm. 2019;25:5(3):518-21 
 
7 Innovation and Value Initiative (IVI). Issue Brief: Aligning vale assessment with treatment in chronic diseases. Value Blueprints. 9 
December 2019  
https://www.thevalueinitiative.org/wp-content/uploads/2019/12/Value-Blueprint_Aligning-Value-Assessment-with-
Treatment_FINAL.pdf 
 
8 Langley PC. Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure. Inov Pharm. 
2016;7(3): No. 6 https://pubs.lib.umn.edu/index.php/innovations/article/view/449 
 
                                                 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 11, No. 1, Article 2                          INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i1.2402 
15 
 
                                                                                                                                                                                     
9 Langley PC. Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report of the Institute for Clinical and 
Economic Review (ICER). Inov Pharm. 2017;8(1): No. 12 https://pubs.lib.umn.edu/index.php/innovations/article/view/492 
 
10 Langley PC. Imaginary Worlds and the Institute for Clinical and Economic Review (ICER) Evidence Report: Targeted Immune 
Modulators for Rheumatoid Arthritis. Inov Pharm. 2017;8(2): No. 10. 
https://pubs.lib.umn.edu/index.php/innovations/article/view/515 
 
11 Langley PC. Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors. Inov Pharm. 2017;8(2): No. 11 
https://pubs.lib.umn.edu/index.php/innovations/article/view/516 
 
12 Langley PC. Another Imaginary World: The ICER Claims for the Long-Term Cost-Effectiveness and Pricing of Vesicular Monoamine 
Transporter 2 (VMAT2) Inhibitors in Tardive Dyskinesia. Inov Pharm. 2017;8(4): No 12 
https://pubs.lib.umn.edu/index.php/innovations/article/view/927 
 
13 Neumann P, Willke R, Garrison L. A health economics approach to US value assessment frameworks – Introduction: An ISPOR 
Special Task Force Report (1). Value Health. 2018;21:119-123 
 
14 McKenna S, Doward L, Niero M et al. Development of needs-based quality of life instruments. Value Health. 2004;7(Supp1):S17-
S21 
 
15 Doward L, McKenna S, Meads D. Effectiveness of needs-based quality of life instruments. Value Health. 2004;7(Supp 1):S35-S38 
 
16 Tennant A, McKenna S, Hagell P. Application of Rasch Analysis in the Development and application of quality of life instruments. 
Value Health. 2004;7(Suppl 1):S22-S26 
 
17 Bond T, Fox C. Applying the Rasch Model (3rd  Ed.). New York: Routledge, 2015   
 
18 McKenna S, Wilburn J. Patient value: its nature, measurement, and role in real world evidence studies and outcomes-based 
reimbursement. J Med Econ. 2018;21(5):464-80 
 
19 McKenna S, Heaney A, Wilburn J et al. Measurement of patient reported outcomes 1: The search for the Holy Grail. J Med Econ. 
2019;22(6):516-522 
 
20 McKenna S, Heaney A, Wilburn J. et al. Measurement of patient-reported outcomes. 2: Are current measures failing us? J Med 
Econ. 2019;22(6):523-30  
 
21 Langley PC. Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER Value Assessment Update. Inov 
Pharm. 2017;8(4): No 7 https://pubs.lib.umn.edu/index.php/innovations/article/view/933 
 
22 Langley PC. Transparency, Imaginary Worlds and ICER Value Assessments. Inov Pharm.  2017;8(4): No 11 
https://pubs.lib.umn.edu/index.php/innovations/article/view/926  
 
23 Langley PC. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds. Inov Pharm. 
2018;9(2): No. 10 https://pubs.lib.umn.edu/index.php/innovations/article/view/1300 
 
24 ICER. RA Update: Revised Scoping Document 9 May, 2019 https://icer-review.org/material/ra-update-revised-scoping-document/ 
 
25 ICER. RA Update: Draft Scoping Document 11 April 2019 https://icer-review.org/material/ra-update-draft-scoping-document/ 
 
26 ICER. RA Update: Public Comment on Draft Scoping Document. https://icer-review.org/material/ra-update-public-comment-on-
draft-scoping-document/ 
27 Arthritis Foundation, April 30 2019 https://icer-review.org/wp-
content/uploads/2019/03/ICER_RA_Update_Draft_Scope_Comments_050919.pdf 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 11, No. 1, Article 2                          INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i1.2402 
16 
 
                                                                                                                                                                                     
28 ICER. RA Update: Updated Scoping Document. June 2019 https://icer-review.org/material/ra-update-updated-scoping-document/ 
 
29 Wootton D. The Invention of Science: A new history of the scientific revolution. New York: Harper Collins, 2015.  
 
30 Popper KR., The logic of scientific discovery .New York: Harper, 1959. 
 
31 Lakatos I, Musgrave A (eds.). Criticism and the growth of knowledge. Cambridge: University Press, 1970. 
 
32 Piglucci M. Nonsense on Stilts: How to tell science from bunk. Chicago: University of Chicago Press, 2010) 
 
33 Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: 
Canada. Ottawa: CADTH, 2017 
 
34 Langley P. ICER, ISPOR AND QALYs: A Tale of Imaginary Worlds. Inov Pharm. 2019;10(4):article 10 
https://pubs.lib.umn.edu/index.php/innovations/article/view/2266 
 
35 Dawkins R. The Selfish Gene (30th Anniversary Ed). Oxford: University Press, 2006 
  
36 Magee B. Popper. London; Fontana, 1973 
 
37 Langley PC.  Imaginary worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 
2015. Inov Pharm. 2016;7(2): Article 9. 
https://pubs.lib.umn.edu/index.php/innovations/article/view/432 
 
38 Langley PC, Rhee TG.  Imaginary worlds: A systematic review of the status of modeled cost-effectiveness claims published in the 
Journal of Medical Economics from January 2015 to December 2015.  Inov Pharm. 2016;7(2): Article 16. 
https://pubs.lib.umn.edu/index.php/innovations/article/view/439 
 
39Langley PC, Rhee TG. Imaginary worlds: The status of modeled economic evaluation claims published in Value in Health January 
2015 to December 2015. Inov Pharm. 2016;7(2): Article 18.  
 https://pubs.lib.umn.edu/index.php/innovations/article/view/441 
 
40 Langley PC, Rhee TG.  Imaginary worlds: A systematic review of the status of modeled cost-effectiveness claims published in the 
Journal of Medical Economics from January 2015 to December 2015.  Inov Pharm. 2016;7(2): Article 16. 
https://pubs.lib.umn.edu/index.php/innovations/article/view/538 
 
41 Langley PC, Rhee T. The Imaginary Worlds of ISPOR: Modeled Cost-Effectiveness Claims Published in Value in Health from January 
2016 to December 2016. Inov Pharm. 2017;8(2): Article 14  
https://pubs.lib.umn.edu/index.php/innovations/article/view/538 
42 Langley PC. Validation of modeled pharmacoeconomic claims in formulary submissions. J Med Econ. 2015;18(12):993-99  
43 Langley PC. Modeling imaginary worlds: Version 4 of the AMCP Format for Formulary Submissions. Inov Pharm. 2016;7(2): No. 11 
https://pubs.lib.umn.edu/index.php/innovations/article/view/434 
 
44 Brazier J, Ara R, Azzabi J et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good 
Practices for Outcomes Research Task Force Report. Value Health;2019;22:267-75 
 
45 Langley PC. Great Expectations: Cost-utility models as decision criteria. Inov Pharm. 2016:7(2); Article 14 
https://pubs.lib.umn.edu/index.php/innovations/article/view/437 
 
46 NICE. Position statement on use of EQ-5D-5L valuation set for England (updated November 2019)   
https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 11, No. 1, Article 2                          INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i1.2402 
17 
 
                                                                                                                                                                                     
47 Drummond M, Sculpher M, Torrance et al. Methods for the Economic Evaluation of Health Care Programmes 3rd Ed. Oxford 
University Press, 2005. 
 
48 Grimby G, Tennant AQ, Tesio L. The use of raw scores from ordinal scales: Time to end malpractice? (Editorial). J Rehab Med. 
2012;44:97-98 
 
49 Stevens S. On the theory of scales of measurement. Science. 1946;103:667-680 
 
50 Hunt S, McKenna S, McEwen J et al. A quantitative approach to perceived health status: a validation study. J Epidem Comm Health. 
1980;34:281-86 
 
51 Luce R, Tukey J. Simultaneous conjoint measurement: a new type of fundamental measurement. J Math Psychol. 1964;1:1-27 
  
52 Wailoo A, Hernández-Alava M, Manca A et al. Mapping to Estimate Health-State Utility from Non-Preference-based Outcome 
Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2017;20:18-27 
 
53 ICER. Evidence Report: Targeted Immune Modulators for Rheumatoid Arthritis. April 2017 https://icer-review.org/wp-
content/uploads/2016/08/NE_CEPAC_RA_Evidence_Report_FINAL_040717.pdf 
 
54 ICER. Evidence Report – Oral Semaglutide for Type 2 Diabetes.1 November 2019. https://icer-review.org/wp-
content/uploads/2019/09/ICER_Diabetes_Evidence-Report_110119.pdf 
 
55 Hernández-Alava M, Wailoo A, Grimm S et al. EQ-5D-5L versus EQ-5D-3L; The impact on cost-effectiveness in the United Kingdom. 
Value Health. 2018;21(1):49-56  
 
56 Pennington B, Hernández-Alava M, Pudney S et al. The impact of moving from EQ-5D-3L to -5L in NICE technology appraisals. 
Pharmacoeconomics. 2019;37(1):75-84 
  
57 Hernández-Alava M, Pudney S. Econometric modelling of multiple self-reports of health states: the switch from EQ-5D-3L to EQ-
5D-5L in evaluating drug therapies for rheumatoid arthritis. J Health Econ. 2017;55:139-52 
 
58 Radawski C, Genovese M, Hauber B et al. Patient perceptions of unmet medical need in rheumatoid arthritis A cross-sectional 
survey in the USA. Rheumatol Ther, 2019;6:461-71 
 
59 De Jong Z, van der Heijde D, McKenna S et al. The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific 
quality of life instrument. Br J Rheumatology. 1997;36:878-83 
 
60 Galen Research, Manchester UK  http://www.galen-research.com/content/measures/RAQoL_UK_-_First_page_sample.pdf 
 
61 Heaney A, Stepanous J, Rouse M et al. A review of the psychometric properties and use of the Rheumatoid Arthritis Quality of Life 
Questionnaire (RAQoL) in clinical research. Curr Rheumatol Rev. 2017;13(3):197-205 
 
62 Galen Research, Manchester UK  http://www.galen-research.com/measures-database/ 
 
63 Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing 
spondylitis. Ann Rheum Dis. 2003;62:20–6. 
 
64 Keenan A, McKenna S, Doward L et al. Development and validation of a needs-based quality of life instrument for osteoarthritis. 
Arthritis Rheum. 2008;59(6):841-8 
 
65 McKenna S, Doward L, Whalley D et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann 
Rheum Dis. 2004;63(2):162-9 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 11, No. 1, Article 2                          INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i1.2402 
18 
 
                                                                                                                                                                                     
66 Doward L, McKenna S, Whalley D et al. The development of the L-QoL: a quality of life instrument specific to systemic lupus 
erythematosus. Ann Rheum Dis. 2009;68(2):196-200 
 
67 Tennant A, Conaghan P. The Rasch Measurement Model in rheumatology: what is it and why use it? When should it be applied, 
and what should one look for in a Rasch paper. Arthritis Rheumatism. 2007;57(8):1358-62 
 
68 ICER. Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value - Response to Public Comments on Draft Evidence 
Report. 26 November 2019 https://icer-review.org/wp-
content/uploads/2019/03/ICER_RA_Response_to_Public_Comments_112619.pdf 
 
69 ICER Press Release 26 November 2019  https://icer-review.org/announcements/jak_inhibitor_evidence_report/ 
 
70 Hafström I, Ajeganova S, Andersson M et al. A Swedish register based, long-term inception cohort study of patients with 
rheumatoid arthritis – results of clinical relevance. Open Access Rheumatology Res Reviews. 2019;11:207-217 
 
71 Malm K, Bergman S, Andersson M, et al. Quality of life in patients with established rheumatoid arthritis: A phenomenographic 
study. SAGE Open Medicine. 2017;5:1-8 
 
72 Langley PC. Guidelines for Formulary Evaluation [Proposed]. Program in Social and Administrative Pharmacy. College of Pharmacy. 
University of Minnesota. Version 2.0. December 2016. 
https://www.pharmacy.umn.edu/sites/pharmacy.umn.edu/files/minnesota_guidelines_december_2016.pdf 
 
73 Warzel C. Pierre and the Paradox of Anonymity. New York Times. 30 October 2019 
